Showing results (231-240 of 419) with videos related to

Sort By:
Pageof 42
Molecular Cancer Therapeutics|March 5, 2020
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental TherapiesRoman Groisberg, Jason Roszik, Anthony P Conley, et al.
Oncotarget|August 4, 2016
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsJ Andrew Livingston, Kenneth R Hess, Aung Naing, et al.
JCO Precision Oncology|September 3, 2021
Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard TherapiesAndrew Hendifar, Edik M Blais, Brian Wolpin, et al.
JCO Precision Oncology|February 1, 2022
Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket StudyJulio Peguero, Davendra P S Sohal, Bert H O'Neil, et al.
Lung Cancer (Amsterdam, Netherlands)|January 10, 2024
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastasesSolange Peters, José Trigo, Benjamin Besse, et al.
Oncotarget|July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trialsIshwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
ESMO Open|November 24, 2020
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trialsAndrew W Hahn, Omar Alhalabi, Pavlos Msaouel, et al.
Scientific Reports|February 22, 2020
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignanciesYudong Wang, Filip Janku, Sarina Piha-Paul, et al.
Oncotarget|September 22, 2018
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinicVikas Dembla, Neeta Somaiah, Pedro Barata, et al.
BMC Cancer|June 13, 2021
Food and Drug Administration approvals in phase 3 Cancer clinical trialsJoseph Abi Jaoude, Ramez Kouzy, Marc Ghabach, et al.
Pageof 42